Nurix Therapeutics CEO Arthur Sands' 2023 pay falls 54% to $4.4M
Nurix Therapeutics reports 2023 executive compensation
By ExecPay News
Published: March 27, 2024
Nurix Therapeutics reported fiscal year 2023 executive compensation information on March 27, 2024.
In 2023, three executives at Nurix Therapeutics received on average a compensation package of $2.5M, a 57% decrease compared to previous year.
Average pay of disclosed executives at Nurix Therapeutics
Arthur T. Sands, Chief Executive Officer, received $4.4M in total, which decreased by 54% compared to 2022. 77% of Sands' compensation, or $3.4M, was in option awards. Sands also received $355K in non-equity incentive plan, $591K in salary, as well as $40K in other compensation.
Gwenn Hansen, Chief Scientific Officer, received a compensation package of $1.6M, which decreased by 57% compared to previous year. 41% of the compensation package, or $670K, was in option awards.
Hans van Houte, Chief Financial Officer, earned $1.6M in 2023, a 63% decrease compared to previous year.
Nurix Therapeutics' fiscal year ends on November 30.
Related executives
You may also like
Source: SEC filing on March 27, 2024.